GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Indo-Bangla Pharmaceuticals Ltd (DHA:IBP) » Definitions » Net Income

Indo-Bangla Pharmaceuticals (DHA:IBP) Net Income : BDT0.00 Mil (TTM As of . 20)


View and export this data going back to 2018. Start your Free Trial

What is Indo-Bangla Pharmaceuticals Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Indo-Bangla Pharmaceuticals's Net Income for the six months ended in . 20 was BDT0.00 Mil. Its Net Income for the trailing twelve months (TTM) ended in . 20 was BDT0.00 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Indo-Bangla Pharmaceuticals's Earnings per Share (Diluted) for the six months ended in . 20 was BDT.


Indo-Bangla Pharmaceuticals Net Income Historical Data

The historical data trend for Indo-Bangla Pharmaceuticals's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Indo-Bangla Pharmaceuticals Net Income Chart

Indo-Bangla Pharmaceuticals Annual Data
Trend
Net Income

Indo-Bangla Pharmaceuticals Semi-Annual Data
Net Income

Indo-Bangla Pharmaceuticals Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Indo-Bangla Pharmaceuticals's Net Income for the fiscal year that ended in . 20 is calculated as

Net Income(A: . 20 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=+++0
=0.00

Indo-Bangla Pharmaceuticals's Net Income for the quarter that ended in . 20 is calculated as

Net Income(Q: . 20 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=+++0
=0.00

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income for the trailing twelve months (TTM) ended in . 20 was BDT0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Indo-Bangla Pharmaceuticals  (DHA:IBP) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Indo-Bangla Pharmaceuticals's Earnings per Share (Diluted) (EPS) for the quarter that ended in . 20 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Indo-Bangla Pharmaceuticals Net Income Related Terms

Thank you for viewing the detailed overview of Indo-Bangla Pharmaceuticals's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Indo-Bangla Pharmaceuticals Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ahmed Akbar Sobhan Road, Block B, Plot No. 183, 6th Floor, Bashundhara R/A, Baridhara, Dhaka, BGD, 1229
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.